Beam Therapeutics announced impressive Phase 1/2 data for BEAM-302 in alpha-1 antitrypsin deficiency (AATD), showing 94% correctly folded circulating AAT, 84% drop in faulty enzyme, and average AAT level of 16.1 uM after 60 mg dose.1
Data described as 'impressive' and highest mean serum AAT level from SERPINA1 correction approaches by William Blair analysts, positioning Beam strongest among genetic therapies for AATD.1
Initial safety profile favorable with mostly mild/moderate adverse events; one asymptomatic grade 4 liver enzyme elevation noted.1
Beam plans pivotal expansion of ongoing Phase 1/2 study in second half of 2026, seeking FDA accelerated approval pathway based on biomarker endpoints.12
Analysts at H.C. Wainwright project peak annual revenues of ~$4 billion if approved; aligns with earlier Q1 2026 data update expectations.14
Sources:
1. https://www.biospace.com/drug-development/beams-base-editor-advances-to-pivotal-development-on-back-of-impressive-aatd-data
2. https://insights.citeline.com/scrip/advanced-therapies/gene-therapies/beam-to-extend-current-trial-for-pivotal-beam-302-development-DLT4QUZARBGMBPIIKANSIJMDGM/
4. https://www.globenewswire.com/news-release/2026/01/11/3216497/0/en/Beam-Therapeutics-Sets-Strategic-Priorities-for-its-Genetic-Disease-and-Hematology-Franchises-to-Drive-Execution-of-Late-Stage-Clinical-Programs-and-Extends-its-Operating-Runway-th.html